Overview
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a stable analog of the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg). It has been used clinically in Russia since 2009 as an approved anxiolytic drug (intranasal formulation) for generalized anxiety disorder. Selank is distinguished from benzodiazepines and other anxiolytics by its lack of sedation, muscle relaxation, or dependency potential in published studies. Research has also examined cognitive-enhancing properties including improved memory consolidation and attention.
Mechanism
Selank's mechanism is not fully characterized but involves modulation of the GABAergic system (without direct GABA-A receptor binding), normalization of brain-derived neurotrophic factor (BDNF) levels, and regulation of the serotonin/dopamine balance. It also upregulates the expression of enkephalins (endogenous opioid peptides) and appears to stabilize the Met-enkephalin system. Its immunomodulatory effects — upregulation of IL-2, IFN-γ, and NK cell activity — distinguish it from purely CNS-targeted anxiolytics.
Research Areas
Side Effects (Preclinical)
- – Generally well-tolerated in Russian clinical studies
- – Mild nasal irritation (intranasal route)
- – Rare: transient fatigue or sedation at higher doses
- – No withdrawal or dependency in published studies
Cautions
- – For research use only outside Russia
- – Primary literature is predominantly Russian; limited Western peer-reviewed replication
- – Interaction profile with other CNS-active compounds not fully characterized
Menopause & Women's Health Relevance
Anxiety, irritability, and mood instability are among the most reported — and most undertreated — symptoms of perimenopause and menopause. Selank's research profile in generalized anxiety disorder (without sedation or dependency) makes it a relevant research target for this population. GABAergic modulation may also address the sleep disruption common in the menopausal transition.
What the research shows
Selank’s most notable characteristic in the published literature is its anxiolytic effect without the sedation, cognitive impairment, or dependency risk associated with benzodiazepines. Russian clinical studies in generalized anxiety disorder showed efficacy comparable to medazepam with a more favorable tolerability profile.
Like Epitalon, the primary research base comes from Russian institutions. Independent Western replication is limited, which should be factored into evidence assessment. However, the mechanism-of-action research (BDNF, enkephalin, GABAergic modulation) is biologically plausible and has attracted increasing international interest.
References
- Selank, an analogue of the peptide tuftsin, regulates the processing of information and memory in rats — Semenova TP et al. (2007)
- Anxiolytic effect of Selank peptide — Kozlovskiy SA et al. (2007)